{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:05:10Z","timestamp":1778861110510,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.bmcl.2023.129572","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T17:18:27Z","timestamp":1701451107000},"page":"129572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Optimizing and characterizing 4-methyl substituted pyrazol-3-carboxamides leading to the peripheral cannabinoid 1 receptor inverse agonist TM38837"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2906-2032","authenticated-orcid":false,"given":"Thomas","family":"H\u00f6gberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marie","family":"Receveur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Linget","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pia K.","family":"N\u00f8rregaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul B.","family":"Little","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8925-5940","authenticated-orcid":false,"given":"Martin","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2023.129572_h0005","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.phrs.2009.02.010","volume":"60","author":"Di Marzo","year":"2009","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmcl.2023.129572_h0010","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/ijo.2009.67","volume":"33","author":"Di Marzo","year":"2009","journal-title":"Int J Obesity"},{"key":"10.1016\/j.bmcl.2023.129572_h0015","doi-asserted-by":"crossref","first-page":"6178","DOI":"10.3390\/molecules26206178","volume":"26","author":"O'Sullivan","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2023.129572_h0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1152\/physiol.00029.2020","volume":"36","author":"Rohbeck","year":"2021","journal-title":"Physiology"},{"key":"10.1016\/j.bmcl.2023.129572_h0025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/ph11020055","volume":"11","author":"Horn","year":"2018","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bmcl.2023.129572_h0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1517\/14728210902736568","volume":"14","author":"Janero","year":"2009","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.bmcl.2023.129572_h0035","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1467-789X.2008.00520.x","volume":"10","author":"Akbas","year":"2009","journal-title":"Obes Rev"},{"key":"10.1016\/j.bmcl.2023.129572_h0040","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1007\/s00125-008-1048-2","volume":"51","author":"DiMarzo","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.bmcl.2023.129572_h0045","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2826.2008.01671.x","volume":"20","author":"Mackie","year":"2008","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.bmcl.2023.129572_h0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107477","volume":"208","author":"Cinar","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmcl.2023.129572_h0055","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.2174\/1568026619666190708164841","volume":"19","author":"Nguyen","year":"2019","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.bmcl.2023.129572_h0060","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/med.21418","volume":"37","author":"Nguyen","year":"2017","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmcl.2023.129572_h0065","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2174\/156802609788897844","volume":"9","author":"Lee","year":"2009","journal-title":"Curr Topics Med Chem"},{"key":"10.1016\/j.bmcl.2023.129572_h0070","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.beem.2008.09.001","volume":"23","author":"Scheen","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.bmcl.2023.129572_h0075","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2337\/dc08-0386","volume":"31","author":"Rosenstock","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.bmcl.2023.129572_h0080","first-page":"173","volume":"2","author":"Waterlow","year":"2007","journal-title":"Core Evid"},{"key":"10.1016\/j.bmcl.2023.129572_h0085","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2710.2010.01164.x","volume":"36","author":"Christopoulou","year":"2011","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.bmcl.2023.129572_h0090","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/13543776.2019.1597851","volume":"29","author":"Amato","year":"2019","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bmcl.2023.129572_h0095","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1517\/13543776.2015.1064898","volume":"25","author":"Sharma","year":"2015","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bmcl.2023.129572_b0035","author":"Amengual","year":"2006","journal-title":"PCT Int Appl"},{"key":"#cr-split#-10.1016\/j.bmcl.2023.129572_b0040.1","unstructured":"Patents covering acidic CB1 modulators. M. Cooper, J.-M. Receveur, T. H\u00f6gberg, P.A. Nielsen, J.-M. Linget, P.K. N\u00f8regaard, A. Murray, E. Bjurling (7TM Pharma A\/S, Den.). (a) PCT Int. Appl. (2008), WO 2008075019 A1"},{"key":"#cr-split#-10.1016\/j.bmcl.2023.129572_b0040.2","unstructured":"(b) PCT Int. Appl. (2008), WO 2008075012 A1"},{"key":"#cr-split#-10.1016\/j.bmcl.2023.129572_b0040.3","unstructured":"(c) PCT Int. Appl. (2008), WO 2008075013 A1."},{"key":"10.1016\/j.bmcl.2023.129572_h0110","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1016\/j.bmcl.2011.08.032","volume":"21","author":"Fulp","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2023.129572_h0115","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1016\/j.bmcl.2013.06.066","volume":"23","author":"Chorvat","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2023.129572_b0050","volume":"1 25","author":"Manallack","year":"2007","journal-title":"Med Chem"},{"key":"10.1016\/j.bmcl.2023.129572_b0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bmcl.2009.11.047","volume":"20","author":"Cooper","year":"2010","journal-title":"Med Chem Lett"},{"key":"10.1016\/j.bmcl.2023.129572_b0060","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.bmcl.2009.12.003","volume":"20","author":"Receveur","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2023.129572_b0065","unstructured":"CB1 antagonism was assessed by measuring inhibition of CP55940-induced [35S]GTP\u03c7S binding to membranes prepared from CHO-K1 cells expressing the human CB1 receptor (Harrison and Traynor, Life Sci. 2003, 74, 489). Assessment of inverse agonism was conducted analogously without addition of the agonist CP55940. CB1 receptor binding (Bylund and Toews, Am J Physiol. 1993, 265, L421-9.) was analyzed by measuring displacement of [3H]-CP55940 binding to COS7 or CHO-K1 cells expressing the human CB1 receptor. CP55940 is a non-selective CB1 and CB2 receptor agonist (e.g., Felder et al., Mol. Pharmacol. 1995, 48, 443). Compounds were tested in-house for logDchi and solubility (Valko et al., Curr. Med. Chem. 2001, 8, 1137) and some for metabolic stability in rat\/mouse microsomes. Selected compounds were tested at CEREP for CYP450 interaction and at Sophion for hERG inhibition (patch clamp assay). Nd designations in Tables refer to Not determined."},{"key":"10.1016\/j.bmcl.2023.129572_b0070","unstructured":"H\u00f6gberg, T. Frontiers in Medicinal Chemistry, ACS and EFMC co-organizers, Stockholm, June 19-21, 2011. Lecture on preclinical and clinical results of TM38837 without disclosing structure."},{"key":"10.1016\/j.bmcl.2023.129572_b0075","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bcp.12141","volume":"76","author":"Klumpers","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bmcl.2023.129572_h0150","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/s42255-021-00501-9","volume":"3","author":"Tilg","year":"2021","journal-title":"Nat Metab"},{"key":"10.1016\/j.bmcl.2023.129572_h0155","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2023.129572_b0085","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41374-019-0327-5","volume":"100","author":"Irungbam","year":"2020","journal-title":"Lab Invest"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2300450X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2300450X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T16:06:25Z","timestamp":1726848385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X2300450X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":34,"alternative-id":["S0960894X2300450X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129572","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing and characterizing 4-methyl substituted pyrazol-3-carboxamides leading to the peripheral cannabinoid 1 receptor inverse agonist TM38837","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129572","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"129572"}}